Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP29 Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240)

This Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240) is validated for use in FC, Frozen Sections, Gel Shift, Immunoblotting, IF, IP, Paraffin Sections for the detection of p53 (Ab-3) (Mutant).

Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
OP29
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

Species ReactivityHostAntibody Type
B, Ch, Ht, H, M, RMMonoclonal Antibody

Products

产品目录编号包装 数量 / 包装
OP29-100UGCN 塑胶安瓿;塑胶针药瓶 100 μg
OP29-200UGCN 塑胶安瓿;塑胶针药瓶 200 μg
Description
OverviewRecognizes the ~53 kDa mutant p53 protein under non-denaturing conditions by immunoprecipitation, immunofluorescence, and flow cytometry. Recognizes both mutant and wild-type p53 by immunoblotting and paraffin sections under denaturing conditions.
Catalogue NumberOP29
Brand Family Calbiochem®
References
ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
Barak, Y., et al. 1993. EMBO J. 12, 461.
Kastan, M.B., et al. 1992. Cell 71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
Lane, D.P. 1992. Nature 358, 15.
Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.
Product Information
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Negative controlSK-OV-3 cells
Positive controlA431, Hs27 (wild-type p53), or SK-BR-3 cells or breast carcinoma tissue
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Application ReferencesParaffin Sections Pezzella, F., et al. 1994. J. Clin. Pathol. 47, 592. Original Clone Gannon, J.V., et al. 1990. EMBO J. 9, 1595. Epitope Identification Stephen, C.W. and Lane, D.P., 1992. J. Mol. Biol. 225, 1. Immunofluorescence Bernardi, R., et al. 2004. Nat. Cell Biol. 6, 665.
Key Applications Flow Cytometry
Frozen Sections
Gel Shift
Immunoblotting (Western Blotting)
Immunofluorescence
Immunoprecipitation
Paraffin Sections
Application NotesFlow Cytometry (1-20 µg/ml)
Frozen Sections (10 µg/ml)
Gel Shift (see comments)
Immunoblotting (5 µg/ml)
Immunofluorescence (1-20 µg/ml, see application references)
Immunoprecipitation (1 µg per sample)
Paraffin Sections (see application references)
Application CommentsUnder non-denaturing conditions (immunoprecipitation, immunofluorescence and frozen sections), Anti-p53 (Ab-3) does not recognize normal (wild-type) p53 protein; it recognizes an epitope exposed by activating mutations or denaturation. In denaturing protocols (immunoblotting and paraffin sections), Anti-p53 (Ab-3) will recognize both mutant and wild-type p53. Will not recognize to some p53 molecules with mutations in the RHSVV epitope, but will react to TFIIIA, which has the RHSVV epitope. For gel shift assay, use Cat. No. OP29L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena recombinant protein consisting of amino acids 14-389 of p53 fused to β-galactosidase
ImmunogenHuman
Epitopewithin amino acids 213-217
ClonePAb240
HostMouse
IsotypeIgG₁
Species Reactivity
  • Bovine
  • Chicken
  • Hamster
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
OP29-100UGCN 07790788053888
OP29-200UGCN 04055977208429

Documentation

Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240) MSDS

职位

物料安全数据表 (MSDS) 

Anti-p53 (Ab-3) (Mutant) Mouse mAb (PAb240) 分析证书

标题批号
OP29

参考

参考信息概述
El-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
Barak, Y., et al. 1993. EMBO J. 12, 461.
Kastan, M.B., et al. 1992. Cell 71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
Lane, D.P. 1992. Nature 358, 15.
Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.

小册子

标题
Caspases and other Apoptosis Related Tools Brochure
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision02-October-2007 RFH
ApplicationFlow Cytometry (1-20 µg/ml)
Frozen Sections (10 µg/ml)
Gel Shift (see comments)
Immunoblotting (5 µg/ml)
Immunofluorescence (1-20 µg/ml, see application references)
Immunoprecipitation (1 µg per sample)
Paraffin Sections (see application references)
DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant p53 protein under non-denaturing conditions. Recognizes both the mutant and the wild-type p53 protein under denaturing conditions.
BackgroundThe human p53 tumor suppressor gene encodes a 393 amino acid phosphoprotein that exhibits sequence-specific DNA binding and directly interacts with various cellular and viral proteins. p53 is the most commonly mutated gene in human cancer, with the majority of the mutations being amino acid substitutions. The normal function of p53 is to effect cell cycle arrest at the G1 and G2 checkpoints in response to DNA damage. This checkpoint function is executed by accumulation of p53 followed by induction of the GADD45, WAF1 and MDM2 genes. The current model of p53 function postulates that p53 senses DNA damage and arrests the cell cycle in either the G1 or G2 phases to allow DNA repair to take place. If repair is not successful, p53 initiates programmed cell death, thus preventing the propagation of genetic defects to successive generations of cells.
HostMouse
Immunogen speciesHuman
Immunogena recombinant protein consisting of amino acids 14-389 of p53 fused to β-galactosidase
Epitopewithin amino acids 213-217
ClonePAb240
IsotypeIgG₁
Speciesnot Xenopus, bovine, chicken, hamster, human, mouse, rat
Positive controlA431, Hs27 (wild-type p53), or SK-BR-3 cells or breast carcinoma tissue
Negative controlSK-OV-3 cells
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsUnder non-denaturing conditions (immunoprecipitation, immunofluorescence and frozen sections), Anti-p53 (Ab-3) does not recognize normal (wild-type) p53 protein; it recognizes an epitope exposed by activating mutations or denaturation. In denaturing protocols (immunoblotting and paraffin sections), Anti-p53 (Ab-3) will recognize both mutant and wild-type p53. Will not recognize to some p53 molecules with mutations in the RHSVV epitope, but will react to TFIIIA, which has the RHSVV epitope. For gel shift assay, use Cat. No. OP29L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
Barak, Y., et al. 1993. EMBO J. 12, 461.
Kastan, M.B., et al. 1992. Cell 71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
Lane, D.P. 1992. Nature 358, 15.
Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.
Application referencesParaffin Sections Pezzella, F., et al. 1994. J. Clin. Pathol. 47, 592. Original Clone Gannon, J.V., et al. 1990. EMBO J. 9, 1595. Epitope Identification Stephen, C.W. and Lane, D.P., 1992. J. Mol. Biol. 225, 1. Immunofluorescence Bernardi, R., et al. 2004. Nat. Cell Biol. 6, 665.